An open-label, randomised, phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorctal cancer who are non-eligible for intensive therapy
National Coordinator
Prof.dr. C.J.A. Punt
Academic Medical Center, University of Amsterdam
E-mail: c.punt@amc.uva.nl
First-line treatment of metastatic colorectal cancer in patients non-eligible for intensive therapy
Experimental arm: Trifluridine/tipiracil (TAS-102, Lonsurf) + bevacizumab
Control arm: capecitabine + bevacizumab
Realisatie door Webfresh